$1.25
(Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
7 Years Aggregate
CFO
$-230.88 Mln
EBITDA
$-299.54 Mln
Net Profit
$-310.72 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cortexyme Inc (QNCX)
| -95.0 | 89.1 | 46.7 | -89.2 | -48.8 | -72.4 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Cortexyme Inc (QNCX)
| 79.1 | 77.3 | 64.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Cortexyme Inc (QNCX)
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the... treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Read more
-
CEO & Director
Dr. Dirk Thye M.D.
-
CEO & Director
Dr. Dirk Thye M.D.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cortexyme Inc (QNCX)
What is the current share price of Cortexyme Inc (QNCX) Today?
The share price of Cortexyme Inc (QNCX) is $33.75 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Cortexyme Inc (QNCX) has given a return of -48.84% in the last 3 years.
What is the current PB & PE ratio of Cortexyme Inc (QNCX)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.01 |
-0.03 |
2024 |
-0.01 |
0.01 |
2023 |
-1.44 |
0.53 |
2022 |
0.00 |
0.00 |
2021 |
-0.02 |
0.02 |
What is the 52 Week High and Low of Cortexyme Inc (QNCX)?
The 52-week high and low of Cortexyme Inc (QNCX) are Rs 909.98 and Rs 15.10 as of 31-Aug-2026.
What is the market cap of Cortexyme Inc (QNCX)?
Cortexyme Inc (QNCX) has a market capitalisation of $ 34 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cortexyme Inc (QNCX)?
Before investing in Cortexyme Inc (QNCX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.